How Future Remote Medicine Solutions Will Contain Diseases

The challenges healthcare executives and administrators face are constantly changing. Host Kevin Stevenson talks with the heroes behind the heroes that are enabling hospitals, urgent care centers and telemedicine operators to spend their time tending to patients, while they handle the logistics.

 

Almost everyone is familiar with a stethoscope, and it’s the most common medical device in the world. But many haven’t heard of its digital version. Exploring innovation in healthcare is a pillar of I Don’t Care. Host Kevin Stevenson welcomed Clive Smith, founder and CEO of Thinklabs to talk about his company’s digital stethoscope.

Smith has an electrical engineering background and was researching medical devices. He learned the stethoscope still worked and sounded the way it did when invented in 1816. He spent years researching how to digitize the instrument and bring exceptional sound quality. The first product hit the market in the early 2000s and would find its place in the world of infectious disease outbreaks.

“We worked with units treating Ebola patients in 2014, allowing them to listen to patients while staying protected in their PPE,” Smith said.

So how exactly does the digital stethoscope work? Smith explained, “It’s a round puck that sits on the patient’s twist and can be connected to any type of headphone.”

The “puck” is small, fitting in a hand, but powerful. It would become a highly sought-after medical device during COVID-19, with new challenges. “There were new situations with COVID-19. There was drive-thru testing and a shortage of PPE. We were solving problems in real-time,” Smith said.

The company also learned through a study that the device could be bagged and not dilute the sound. “It can be bagged in many layers without diminishing the sound, so healthcare workers can use pass it around, removing bags to keep it clean.”

Smith noted they are continuing to improve their main product but could innovate on other devices in the future. He also shared his perspective on the future of digital health. “Telemedicine is here to stay, and remote monitoring will evolve to support this. COVID-19 was an accelerant to things already there, but now we see widespread adoption.”

Listen to Previous Episodes of MarketScale’s I Don’t Care Right Here!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More